Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Item
http://www.wikidata.org/entity/Q37059846
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.Prediction of therapy response in ovarian cancer: Where are we now?Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.Role of Protein Linked DNA Breaks in Cancer.Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.The development of PARP as a successful target for cancer therapy.The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
P2860

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Item
http://www.wikidata.org/entity/Q37059846
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I Safety, Pharmacokineti ...... nts with Advanced Solid Tumors
@en
Phase I Safety, Pharmacokineti ...... ts with Advanced Solid Tumors.
@nl
type
label
Phase I Safety, Pharmacokineti ...... nts with Advanced Solid Tumors
@en
Phase I Safety, Pharmacokineti ...... ts with Advanced Solid Tumors.
@nl
prefLabel
Phase I Safety, Pharmacokineti ...... nts with Advanced Solid Tumors
@en
Phase I Safety, Pharmacokineti ...... ts with Advanced Solid Tumors.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
Phase I Safety, Pharmacokineti ...... nts with Advanced Solid Tumors
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-15-0652
P407
P433
P478
P577
P698
P932